PUCHHEIM, Germany--(BUSINESS WIRE)--Sloning BioTechnology GmbH, Puchheim (Munich), a Synthetic Biology company and the technology leader in Gene Synthesis announces today the first closing of a series E financing round. LBBW Venture Capital GmbH, Stuttgart joined existing investors HBM BioVentures, Zurich, KfW Bankengruppe and Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft AG, Jena who also participated in this series E financing round. The proceeds of this first closing with € 4.7m will be used to finance the internationalization of its Slonomics™ gene synthesis business and the further expansion of the unique gene mutant library product family: Slonomax™ - the intelligent library.